Journal of Hepatology
Volume 48, Issue 1 , Pages 5-7 , January 2008

Treatment of hepatitis C in HIV-infected persons: A work in progress

References 

  1. Weber R, Sabin CA, Friis-Moller N, Reiss P, El Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632–1641
  2. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451–459
  3. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839–2848
  4. Nunez M, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, Ocampo A, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses. 2007;23:972–982
  5. Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18:F27–F36
  6. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438–450
  7. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren JD, Palù G, et al. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV-coinfected patients. J Hepatol. 2005;42:615–624
  8. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147–1171
  9. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International Panel. AIDS. 2007;21:1073–1089
  10. Tien PC. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. Am J Gastroenterol. 2005;100:2338–2354
  11. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents. MMWR. 2004;53:1–112
  12. Butt AA, Justice AC, Skanderson M, Good C, Kwoh CK. Rates and predictors of hepatitis C virus treatment in HCV–HIV-coinfected subjects. Aliment Pharmacol Ther. 2006;24:585–591
  13. Zinkernagel AS, von Wyl V, Ledergerber B, Rickenbach M, Furrer H, Battegay M, et al. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antivir Ther. 2006;11:131–142
  14. Mehta SH, Lucas GM, Mirel LB, Torbenson M, Higgins Y, Moore RD, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS. 2006;20:2361–2369
  15. Cacoub P, Halfon P, Rosenthal E, Pialoux G, Benhamou Y, Perronne C, et al. Treatment of hepatitis C virus in human immunodeficiency virus infected patients in “real life”: Modifications in two large surveys between 2004 and 2006. J Hepatol. 2008;48:35–42
  16. Payan C, Pivert A, Morand P, Fafi-Kremer S, Carrat F, Pol S, et al. Rapid and early virological response to chronic hepatitis C treatment with IFN alpha-2b or PEG–IFN alpha-2b plus ribavirin in HIV/HCV co-infected patients. Gut. 2007;56:1111–1116

☆ Dr. Sulkowski declares that he receives research grants or funding/lecture sponsorships/honoraria for continuing medical education (CME) programs from, or advisor or consultant for Boehringer Ingelheim, Human Genome Sciences, Bristol-Myers-Squibb, Novartis, Vertex, Merck, Roche, and Schering, and government grants or research funding R01 DA-11602, DA-16065, and DA-13806. NIH funded study.

PII: S0168-8278(07)00583-1

doi: 10.1016/j.jhep.2007.10.006

Journal of Hepatology
Volume 48, Issue 1 , Pages 5-7 , January 2008

Article Tools